HNN3.0

Project cooperationUpdated on 19 January 2026

NAM: organoids and OoC for drug discovery, and precision medicine applications

full professor at Department of Pharmaceutical Sciences, University of Latvia

Riga, Latvia

About

We develop human-relevant New Approach Methodologies (NAMs) based on patient-derived 3D cultures and organ-on-chip (OoC) platforms. Our expertise includes tumour and matched normal organoids in pancreatic cancer and pancreatitis models, tumour–stroma co-cultures, and drug response profiling.

We have extensive experience in pancreatic cancer, supported by a well-characterised organoid library generated from more than 25 patient surgical resection samples.

We seek to contribute to Horizon Europe consortia by providing validated, scalable, and human-relevant NAMs for translational research, drug discovery, and precision medicine applications.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Type

  • Partner seeks Consortium/Coordinator

Similar opportunities